nodes	percent_of_prediction	percent_of_DWPC	metapath
Levosimendan—TNNC1—Striated Muscle Contraction—TPM3—thyroid cancer	0.0936	0.222	CbGpPWpGaD
Levosimendan—TNNC1—Striated Muscle Contraction—TPM3—thyroid cancer	0.0795	0.188	CbGpPWpGaD
Levosimendan—TNNC1—Muscle contraction—TPM3—thyroid cancer	0.0628	0.149	CbGpPWpGaD
Levosimendan—Haemoglobin decreased—Vandetanib—thyroid cancer	0.0396	0.084	CcSEcCtD
Levosimendan—Haemoglobin decreased—Sorafenib—thyroid cancer	0.0267	0.0567	CcSEcCtD
Levosimendan—KCNJ11—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.0232	0.055	CbGpPWpGaD
Levosimendan—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0229	0.0485	CcSEcCtD
Levosimendan—Atrial fibrillation—Vandetanib—thyroid cancer	0.0209	0.0443	CcSEcCtD
Levosimendan—Cardiac failure—Vandetanib—thyroid cancer	0.0203	0.043	CcSEcCtD
Levosimendan—KCNJ8—SIDS Susceptibility Pathways—RET—thyroid cancer	0.0183	0.0433	CbGpPWpGaD
Levosimendan—Hypokalaemia—Vandetanib—thyroid cancer	0.018	0.0382	CcSEcCtD
Levosimendan—KCNJ8—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.017	0.0402	CbGpPWpGaD
Levosimendan—PDE3A—G alpha (s) signalling events—CALCB—thyroid cancer	0.0159	0.0377	CbGpPWpGaD
Levosimendan—TNNC1—thyroid gland—thyroid cancer	0.0153	0.144	CbGeAlD
Levosimendan—KCNJ8—trachea—thyroid cancer	0.0145	0.136	CbGeAlD
Levosimendan—Cardiac failure—Sorafenib—thyroid cancer	0.0137	0.029	CcSEcCtD
Levosimendan—Cardiac disorder—Vandetanib—thyroid cancer	0.0127	0.027	CcSEcCtD
Levosimendan—Angiopathy—Vandetanib—thyroid cancer	0.0124	0.0263	CcSEcCtD
Levosimendan—Hypokalaemia—Sorafenib—thyroid cancer	0.0121	0.0258	CcSEcCtD
Levosimendan—Mental disorder—Vandetanib—thyroid cancer	0.012	0.0254	CcSEcCtD
Levosimendan—Malnutrition—Vandetanib—thyroid cancer	0.0119	0.0253	CcSEcCtD
Levosimendan—KCNJ8—thyroid gland—thyroid cancer	0.0115	0.108	CbGeAlD
Levosimendan—KCNJ8—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.0113	0.0267	CbGpPWpGaD
Levosimendan—KCNJ8—head—thyroid cancer	0.0102	0.0957	CbGeAlD
Levosimendan—Nervous system disorder—Vandetanib—thyroid cancer	0.00954	0.0202	CcSEcCtD
Levosimendan—TNNC1—lymph node—thyroid cancer	0.00952	0.0893	CbGeAlD
Levosimendan—KCNJ11—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.00941	0.0223	CbGpPWpGaD
Levosimendan—KCNJ11—thyroid gland—thyroid cancer	0.00937	0.0879	CbGeAlD
Levosimendan—PDE3A—thyroid gland—thyroid cancer	0.00918	0.0861	CbGeAlD
Levosimendan—KCNJ8—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00892	0.0211	CbGpPWpGaD
Levosimendan—Insomnia—Vandetanib—thyroid cancer	0.00879	0.0187	CcSEcCtD
Levosimendan—Cardiac disorder—Sorafenib—thyroid cancer	0.00857	0.0182	CcSEcCtD
Levosimendan—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00839	0.0178	CcSEcCtD
Levosimendan—Angiopathy—Sorafenib—thyroid cancer	0.00838	0.0178	CcSEcCtD
Levosimendan—KCNJ11—head—thyroid cancer	0.00832	0.078	CbGeAlD
Levosimendan—Constipation—Vandetanib—thyroid cancer	0.00831	0.0176	CcSEcCtD
Levosimendan—Mental disorder—Sorafenib—thyroid cancer	0.00809	0.0172	CcSEcCtD
Levosimendan—Malnutrition—Sorafenib—thyroid cancer	0.00804	0.0171	CcSEcCtD
Levosimendan—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00752	0.016	CcSEcCtD
Levosimendan—KCNJ11—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.0074	0.0175	CbGpPWpGaD
Levosimendan—PDE3A—G alpha (s) signalling events—TSHR—thyroid cancer	0.00736	0.0174	CbGpPWpGaD
Levosimendan—KCNJ8—lymph node—thyroid cancer	0.00715	0.067	CbGeAlD
Levosimendan—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00696	0.0148	CcSEcCtD
Levosimendan—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00679	0.0144	CcSEcCtD
Levosimendan—Diarrhoea—Vandetanib—thyroid cancer	0.00665	0.0141	CcSEcCtD
Levosimendan—Nervous system disorder—Sorafenib—thyroid cancer	0.00643	0.0136	CcSEcCtD
Levosimendan—Dizziness—Vandetanib—thyroid cancer	0.00643	0.0136	CcSEcCtD
Levosimendan—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00629	0.0133	CcSEcCtD
Levosimendan—Vomiting—Vandetanib—thyroid cancer	0.00618	0.0131	CcSEcCtD
Levosimendan—Headache—Vandetanib—thyroid cancer	0.00609	0.0129	CcSEcCtD
Levosimendan—KCNJ11—lymph node—thyroid cancer	0.00582	0.0546	CbGeAlD
Levosimendan—Nausea—Vandetanib—thyroid cancer	0.00578	0.0123	CcSEcCtD
Levosimendan—PDE3A—lymph node—thyroid cancer	0.0057	0.0535	CbGeAlD
Levosimendan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00566	0.012	CcSEcCtD
Levosimendan—Constipation—Sorafenib—thyroid cancer	0.00561	0.0119	CcSEcCtD
Levosimendan—PDE3A—G alpha (s) signalling events—CALCA—thyroid cancer	0.00551	0.0131	CbGpPWpGaD
Levosimendan—KCNJ8—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00536	0.0127	CbGpPWpGaD
Levosimendan—Cardiac failure—Epirubicin—thyroid cancer	0.00505	0.0107	CcSEcCtD
Levosimendan—Cardiac failure—Doxorubicin—thyroid cancer	0.00468	0.00992	CcSEcCtD
Levosimendan—Hypokalaemia—Epirubicin—thyroid cancer	0.00449	0.00952	CcSEcCtD
Levosimendan—Diarrhoea—Sorafenib—thyroid cancer	0.00449	0.00952	CcSEcCtD
Levosimendan—Dizziness—Sorafenib—thyroid cancer	0.00434	0.0092	CcSEcCtD
Levosimendan—Vomiting—Sorafenib—thyroid cancer	0.00417	0.00885	CcSEcCtD
Levosimendan—Hypokalaemia—Doxorubicin—thyroid cancer	0.00415	0.00881	CcSEcCtD
Levosimendan—Headache—Sorafenib—thyroid cancer	0.00411	0.00872	CcSEcCtD
Levosimendan—Nausea—Sorafenib—thyroid cancer	0.0039	0.00827	CcSEcCtD
Levosimendan—PDE3A—GPCR downstream signaling—CALCB—thyroid cancer	0.00326	0.00773	CbGpPWpGaD
Levosimendan—Cardiac disorder—Epirubicin—thyroid cancer	0.00317	0.00672	CcSEcCtD
Levosimendan—Angiopathy—Epirubicin—thyroid cancer	0.0031	0.00657	CcSEcCtD
Levosimendan—Mental disorder—Epirubicin—thyroid cancer	0.00299	0.00634	CcSEcCtD
Levosimendan—Malnutrition—Epirubicin—thyroid cancer	0.00297	0.0063	CcSEcCtD
Levosimendan—PDE3A—Signaling by GPCR—CALCB—thyroid cancer	0.00296	0.00702	CbGpPWpGaD
Levosimendan—Cardiac disorder—Doxorubicin—thyroid cancer	0.00293	0.00622	CcSEcCtD
Levosimendan—Angiopathy—Doxorubicin—thyroid cancer	0.00286	0.00608	CcSEcCtD
Levosimendan—KCNJ8—Neuronal System—BRAF—thyroid cancer	0.00279	0.0066	CbGpPWpGaD
Levosimendan—Mental disorder—Doxorubicin—thyroid cancer	0.00277	0.00587	CcSEcCtD
Levosimendan—Malnutrition—Doxorubicin—thyroid cancer	0.00275	0.00583	CcSEcCtD
Levosimendan—Nervous system disorder—Epirubicin—thyroid cancer	0.00238	0.00504	CcSEcCtD
Levosimendan—Tachycardia—Epirubicin—thyroid cancer	0.00237	0.00502	CcSEcCtD
Levosimendan—PDE3A—Hemostasis—PRKAR1A—thyroid cancer	0.00235	0.00557	CbGpPWpGaD
Levosimendan—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.00235	0.00556	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—MINPP1—thyroid cancer	0.00232	0.0055	CbGpPWpGaD
Levosimendan—Hypotension—Epirubicin—thyroid cancer	0.00227	0.00481	CcSEcCtD
Levosimendan—Nervous system disorder—Doxorubicin—thyroid cancer	0.0022	0.00467	CcSEcCtD
Levosimendan—Insomnia—Epirubicin—thyroid cancer	0.00219	0.00465	CcSEcCtD
Levosimendan—Tachycardia—Doxorubicin—thyroid cancer	0.00219	0.00465	CcSEcCtD
Levosimendan—Hypotension—Doxorubicin—thyroid cancer	0.0021	0.00445	CcSEcCtD
Levosimendan—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00209	0.00444	CcSEcCtD
Levosimendan—Constipation—Epirubicin—thyroid cancer	0.00207	0.0044	CcSEcCtD
Levosimendan—Insomnia—Doxorubicin—thyroid cancer	0.00203	0.0043	CcSEcCtD
Levosimendan—KCNJ11—Metabolism—NDUFA13—thyroid cancer	0.00197	0.00468	CbGpPWpGaD
Levosimendan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00194	0.00411	CcSEcCtD
Levosimendan—Constipation—Doxorubicin—thyroid cancer	0.00192	0.00407	CcSEcCtD
Levosimendan—KCNJ11—Metabolism—CHST14—thyroid cancer	0.00186	0.0044	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—CALCB—thyroid cancer	0.00175	0.00415	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—TRIM33—thyroid cancer	0.00166	0.00393	CbGpPWpGaD
Levosimendan—Diarrhoea—Epirubicin—thyroid cancer	0.00166	0.00352	CcSEcCtD
Levosimendan—Dizziness—Epirubicin—thyroid cancer	0.0016	0.0034	CcSEcCtD
Levosimendan—PDE3A—Hemostasis—IFNA2—thyroid cancer	0.00156	0.00369	CbGpPWpGaD
Levosimendan—Vomiting—Epirubicin—thyroid cancer	0.00154	0.00327	CcSEcCtD
Levosimendan—Diarrhoea—Doxorubicin—thyroid cancer	0.00153	0.00326	CcSEcCtD
Levosimendan—Headache—Epirubicin—thyroid cancer	0.00152	0.00322	CcSEcCtD
Levosimendan—PDE3A—GPCR downstream signaling—TSHR—thyroid cancer	0.00151	0.00358	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—HPGD—thyroid cancer	0.0015	0.00355	CbGpPWpGaD
Levosimendan—Dizziness—Doxorubicin—thyroid cancer	0.00148	0.00315	CcSEcCtD
Levosimendan—Nausea—Epirubicin—thyroid cancer	0.00144	0.00306	CcSEcCtD
Levosimendan—Vomiting—Doxorubicin—thyroid cancer	0.00143	0.00303	CcSEcCtD
Levosimendan—Headache—Doxorubicin—thyroid cancer	0.00141	0.00298	CcSEcCtD
Levosimendan—PDE3A—Signaling by GPCR—TSHR—thyroid cancer	0.00137	0.00325	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00135	0.0032	CbGpPWpGaD
Levosimendan—Nausea—Doxorubicin—thyroid cancer	0.00133	0.00283	CcSEcCtD
Levosimendan—KCNJ11—Neuronal System—BRAF—thyroid cancer	0.00132	0.00313	CbGpPWpGaD
Levosimendan—KCNJ8—Neuronal System—HRAS—thyroid cancer	0.00128	0.00304	CbGpPWpGaD
Levosimendan—PDE3A—GPCR downstream signaling—SST—thyroid cancer	0.00117	0.00278	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—PTCH1—thyroid cancer	0.00117	0.00276	CbGpPWpGaD
Levosimendan—PDE3A—GPCR downstream signaling—CALCA—thyroid cancer	0.00113	0.00268	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—TCF7L1—thyroid cancer	0.00111	0.00262	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—SST—thyroid cancer	0.00107	0.00253	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—CALCA—thyroid cancer	0.00103	0.00243	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—CDK1—thyroid cancer	0.00093	0.0022	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—TPR—thyroid cancer	0.00086	0.00204	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—PRKAR1A—thyroid cancer	0.000846	0.002	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—TSHR—thyroid cancer	0.00081	0.00192	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000797	0.00189	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—MEN1—thyroid cancer	0.000762	0.00181	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—PTCH1—thyroid cancer	0.000689	0.00163	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—SLC5A5—thyroid cancer	0.000643	0.00152	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—SST—thyroid cancer	0.00063	0.00149	CbGpPWpGaD
Levosimendan—KCNJ11—Neuronal System—HRAS—thyroid cancer	0.000607	0.00144	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—CALCA—thyroid cancer	0.000607	0.00144	CbGpPWpGaD
Levosimendan—PDE3A—Hemostasis—NRAS—thyroid cancer	0.000581	0.00138	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—CDK1—thyroid cancer	0.000549	0.0013	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—RXRA—thyroid cancer	0.000541	0.00128	CbGpPWpGaD
Levosimendan—PDE3A—Hemostasis—KRAS—thyroid cancer	0.0005	0.00118	CbGpPWpGaD
Levosimendan—PDE3A—Hemostasis—TP53—thyroid cancer	0.000444	0.00105	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—NRG1—thyroid cancer	0.000441	0.00104	CbGpPWpGaD
Levosimendan—PDE3A—Hemostasis—HRAS—thyroid cancer	0.000425	0.00101	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—TERT—thyroid cancer	0.000396	0.000938	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—HIF1A—thyroid cancer	0.000378	0.000897	CbGpPWpGaD
Levosimendan—PDE3A—Hemostasis—AKT1—thyroid cancer	0.000375	0.000889	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—PPARG—thyroid cancer	0.000341	0.000809	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—NRAS—thyroid cancer	0.000333	0.00079	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—BRAF—thyroid cancer	0.000313	0.000743	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—KRAS—thyroid cancer	0.000287	0.00068	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—PTGS2—thyroid cancer	0.000269	0.000636	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—HRAS—thyroid cancer	0.000244	0.000578	CbGpPWpGaD
Levosimendan—PDE3A—GPCR downstream signaling—AKT1—thyroid cancer	0.000237	0.000562	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—PTEN—thyroid cancer	0.000234	0.000555	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—CCND1—thyroid cancer	0.000229	0.000542	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—PTEN—thyroid cancer	0.000221	0.000523	CbGpPWpGaD
Levosimendan—PDE3A—Signaling by GPCR—AKT1—thyroid cancer	0.000215	0.00051	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—NRAS—thyroid cancer	0.000197	0.000467	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—KRAS—thyroid cancer	0.00017	0.000402	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—TP53—thyroid cancer	0.000151	0.000357	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—HRAS—thyroid cancer	0.000144	0.000341	CbGpPWpGaD
Levosimendan—KCNJ11—Metabolism—AKT1—thyroid cancer	0.000135	0.00032	CbGpPWpGaD
Levosimendan—PDE3A—Signaling Pathways—AKT1—thyroid cancer	0.000127	0.000301	CbGpPWpGaD
